Angiotensin-converting enzyme inhibitors (ACE-i) and angiotensin II receptor blockers (ARB) for hypertension were prescribed to 75.4% of the patients, while hyperlipidemia was treated mainly with statins (90.4%). The gene discussed is ACE; the disease is hyperlipidemia.